Breaking News

Covance, M2Gen in Patient Recruitment Pact

February 26, 2013

Aims to match patients for biomarker oncology trials

Covance and M2Gen have entered into an exclusive alliance and services agreement to offer patient recruitment services matching potential patients for biomarker-driven oncology trials with the right treatment. Also, Covance will serve as M2Gen’s preferred provider for DNA/RNA sequencing, gene expression analysis, and genotyping analysis services, which will be conducted at its genomics lab in Seattle, WA.
 
"Working together, Covance and M2Gen expect to help biopharmaceutical companies accelerate their drug development programs, make better decisions, and improve their efforts to develop targeted therapies for cancer patients," said Ken Somberg, M.D., chief medical officer for Covance and vice president, Clinical Development Services. "M2Gen’s database is unique in the industry, with clinical data captured and maintained over the cancer patient’s lifetime.  This alliance will help us partner with sponsors as the field of personalized medicine continues to evolve, and as we work toward a common goal of bringing new life-saving medicines to patients who need them.”
 
”M2Gen considers Covance to be an ideal strategic partner with the goal of connecting patients to the best treatment options, including clinical trials, by accelerating the discovery and delivery of personalized medicine,” said Bill Dalton, Ph.D., M.D., president and chief executive officer of M2Gen. 
 
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research